New research suggests that people who come off new slimming jabs like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who halt conventional diet and exercise programs.
Published data in a leading health publication demonstrates that while overweight people often shed a large proportion of their body weight while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"People using these medications should be aware of the risk of rapid rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment weight within about one and a half years.
Comparing Therapies
The research, which examined dozens of studies involving thousands of patients, compared the outcomes of the injectable medications with older methods.
The team emphasize that individuals who lose weight through diet and exercise generally have a more gradual creep back—perhaps 100 grams monthly—once they finish.
Explaining the Quick Regain
Doctors propose the mode of action of the drugs accounts for the accelerated rebound.
The injections imitate a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its endogenous hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement means appetite is no longer kept in check, making excessive eating far more likely."
A Lifelong Condition?
The NHS recommend the injections for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, considering the likelihood of relapse, the therapy should be considered life-long.
This perspective is reinforced by drug manufacturers, who note that the findings "underscore the chronic nature of excess weight," comparing it to managing conditions like hypertension.
User Accounts
Individuals who have stopped the jabs describe a intense return of cravings.
"I experienced something activating and you're instantly ravenous," recalled one woman.
This challenge is worsened if users have not adopted lasting dietary or behavioural modifications during treatment.
Growing Interest
Survey data indicate that millions of people in the UK have used these injections in the past year, with interest being substantial.
- Adoption is greater among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Finally, experts emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone cure and long-term success relies on ongoing behavioural management.
